NCT06309277View on ClinicalTrials.gov

A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

GM-1020

N-methyl-D-aspartate (NMDA) receptor antagonist

Trial Locations (1)

Unknown

RECRUITING

MAC Clinical Research, Manchester

Sponsors
All Listed Sponsors
lead

Gilgamesh Pharmaceuticals

INDUSTRY